Selecta Biosciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Selecta Biosciences, Inc.
Swedish Orphan Biovitrum’s financial performance in the second quarter was held back by COVID-19 related events, but it has left its financial guidance unchanged for 2020.
Merck pays undisclosed upfront fees and promises up to $500m for milestones under licensing and collaboration agreement. Meanwhile, Tetraphase and Xerava are being acquired by La Jolla, after previous bids by Melinta and AcelRx.
Swedish Orphan Biovitrum has taken a stake in Selecta and got access to SEL-212, which it is hoping will win a head-to-head trial against Horizon's Krystexxa, the gold standard for chronic refractory gout.
Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage Ironwood’s GI expertise for givosiran in acute hepatic porphyria and Ultragenyx snags option to buy GeneTx.
- Gene Therapy, Cell Therapy
- Large Molecule
- Nanotechnology, Chips, etc.